HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-8.31%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$972M
AUM Growth
+$972M
(-33%)
Cap. Flow
-$367M
Cap. Flow
% of AUM
-37.78%
Top 10 Holdings %
Top 10 Hldgs %
50.21%
Holding
77
New
12
Increased
11
Reduced
25
Closed
20
Top Buys
| 1 |
Hologic
HOLX
|
$27.9M |
| 2 |
Cigna
CI
|
$25.4M |
| 3 |
Eli Lilly
LLY
|
$22.9M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$18.2M |
| 5 |
Agilent Technologies
A
|
$16.4M |
Top Sells
| 1 |
Envista
NVST
|
$44.5M |
| 2 |
AbbVie
ABBV
|
$41.2M |
| 3 |
Teleflex
TFX
|
$35.2M |
| 4 |
Abbott
ABT
|
$31M |
| 5 |
CVS Health
CVS
|
$29M |
Sector Composition
| 1 | Healthcare | 96.07% |
| 2 | Consumer Discretionary | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $84.4M | 8.48% | 413,640 +11,980 | +3% | +$2.44M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $72.1M | 7.24% | 903,850 +193,740 | +27% | +$15.5M |
|
3
Boston Scientific
BSX
$156B
| $67.4M | 6.77% | 1,807,990 -42,460 | -2% | -$1.58M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $61.4M | 6.17% | 740,948 -28,068 | -4% | -$2.33M |
|
5
Centene
CNC
$14.3B
| $45.8M | 4.6% | 540,860 -93,750 | -15% | -$7.93M |
|
6
UnitedHealth
UNH
$281B
| $35M | 3.52% | 68,230 -4,350 | -6% | -$2.23M |
|
7
Natera
NTRA
$23.1B
| $31.8M | 3.2% | 898,420 -551,116 | -38% | -$19.5M |
|
8
Bristol-Myers Squibb
BMY
$96B
| $31.8M | 3.19% | 412,420 -117,740 | -22% | -$9.07M |
|
9
LivaNova
LIVN
$3.08B
| $30.4M | 3.05% | 486,550 -15,800 | -3% | -$987K |
|
|
10
Hologic
HOLX
$14.9B
| $27.9M | 2.8% | +402,110 | New | +$27.9M |
|
11
Tenet Healthcare
THC
$16.3B
| $27.3M | 2.74% | 518,990 +235,260 | +83% | +$12.4M |
|
|
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
| $27.2M | 2.73% | 1,097,370 +140,630 | +15% | +$3.48M |
|
13
Elevance Health
ELV
$71.8B
| $26.2M | 2.63% | 54,230 -19,120 | -26% | -$9.23M |
|
|
14
Cigna
CI
$80.3B
| $25.4M | 2.55% | +96,470 | New | +$25.4M |
|
15
Danaher
DHR
$147B
| $24.6M | 2.47% | 96,880 -610 | -0.6% | -$155K |
|
|
16
Eli Lilly
LLY
$657B
| $22.9M | 2.3% | +70,630 | New | +$22.9M |
|
17
Cencora
COR
$56.5B
| $22.2M | 2.23% | 156,910 -174,000 | -53% | -$24.6M |
|
18
Humana
HUM
$36.5B
| $22.1M | 2.22% | 47,220 -61,820 | -57% | -$28.9M |
|
|
19
Abbott
ABT
$231B
| $21.7M | 2.18% | 199,300 -285,440 | -59% | -$31M |
|
|
RVNC
20
DELISTED
Revance Therapeutics, Inc.
RVNC
| $19.6M | 1.97% | 1,418,088 -5,337 | -0.4% | -$73.8K |
|
21
Henry Schein
HSIC
$8.44B
| $19.1M | 1.92% | 248,920 -6,310 | -2% | -$484K |
|
22
Cytokinetics
CYTK
$4.23B
| $19.1M | 1.92% | 485,600 -649,510 | -57% | -$25.5M |
|
|
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
| $18.2M | 1.83% | +103,060 | New | +$18.2M |
|
24
Incyte
INCY
$16.5B
| $17.8M | 1.79% | 234,130 -266,270 | -53% | -$20.2M |
|
25
Syndax Pharmaceuticals
SNDX
$1.41B
| $17.8M | 1.79% | 923,400 -257,100 | -22% | -$4.95M |
|